Sonoco Products reports today with options traders suddenly far more cautious than they were a week ago — a sharp contrast to the broadly calm picture that prevailed heading into the original July 22 date.
The clearest change since the prior preview is in the options market. The put/call ratio has jumped to 0.81, nearly three standard deviations above its 20-day average of 0.49 — a z-score of 2.89 that marks the most defensive options posture in months. A week ago the PCR sat around 0.47 with a flat z-score. That shift is material. Options traders who were indifferent to downside risk a week ago are now actively buying protection into the print. Short interest has nudged a little higher too, reaching 10.6% of free float — up roughly 17% over the past month — though the pace of that build has slowed. Availability remains comfortable at 223%, and borrowing costs are a modest 0.54%, so the lending market is not flashing distress. The stock itself has recovered: up 9% over the past month to $55.15, and gaining another 2.6% on the week.
The bull and bear debate narrows to a single question — can Sonoco deliver on its 2026 EBITDA guidance of $1.25–1.35 billion while absorbing input cost pressure and Eviosys integration costs? Bulls point to improving industrial packaging demand, international expansion, and the portfolio cleanup following the Eviosys deal as levers for margin expansion and a potential multiple re-rate. The analyst community has moved in their direction recently: B of A Securities raised its target to $69 this month while maintaining Buy, and Citigroup lifted to $66. Truist trimmed slightly to $64 but kept its Buy rating. The consensus mean target of $62 sits roughly 12% above the current price. Bears counter that the last print was punishing — the stock fell 13% in a single session following Q1 results in April, and was still down 13% five days later — with lower prices, moderating volumes, and uncertain cash flow beyond 2026 all weighing on the thesis.
The institutional holder base offers little drama: BlackRock holds 11.5% of shares and added modestly in Q2. The more notable insider signal came from the CFO, who purchased roughly $400,000 worth of stock at $49.64 in late April — right after the Q1 selloff — alongside a divisional president adding another $340,000. The subsequent 11% recovery from those levels gives that buying cluster some credibility as a floor signal, though the CFO also sold a small parcel at $56.35 at end of June.
Today's print is less a test of whether Sonoco is growing and more a test of whether the Eviosys integration is tracking to plan, input costs are being absorbed without margin damage, and the full-year EBITDA range still holds — the answers to those three questions will determine whether the April selloff was an overreaction or a warning.
See the live data behind this article on ORTEX.
Open SON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
